UPenn sues Genentech over patent infringement with four cancer drugs
The University of Pennsylvania is suing Roche’s Genentech again, this time seeking an unidentified amount of damages for infringing on a Penn patent that’s linked to four of the California biotech’s cancer treatments and which has helped bring in billions in sales over the years.
The patent in question from 2009 — known as the ‘588 patent — relates to therapies for treating ErbB protein-mediated cancer tumors, which relate to Genentech’s cancer drugs Herceptin, Herceptin Hylecta, Perjeta, and Phesgo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.